Ownership history in CAXTON ASSOCIATES LP · 8 quarters on record
This page tracks every 13F SEC filing in which CAXTON ASSOCIATES LP reported a position in EDITAS MEDICINE INC (EDIT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2024 Q3 | REDUCED | 114,363 | -14,147 | -11.0% | 0.01% | $390K | $3.41 |
| 2024 Q2 | ADDED | 128,510 | +95,957 | +294.8% | 0.02% | $600K | $4.67 |
| 2023 Q4 | REDUCED | 32,553 | -28,670 | -46.8% | 0.02% | $330K | $10.13 |
| 2023 Q3 | ADDED | 61,223 | +27,678 | +82.5% | 0.07% | $478K | $7.80 |
| 2023 Q2 | REDUCED | 33,545 | -74,163 | -68.9% | 0.04% | $276K | $8.23 |
| 2023 Q1 | ADDED | 107,708 | +93,375 | +651.5% | 0.12% | $781K | $7.25 |
| 2022 Q4 | REDUCED | 14,333 | -2,768 | -16.2% | 0.01% | $127K | $8.87 |
| 2022 Q2 | INITIATED | 17,101 | — | — | 0.02% | $202K | $11.83 |
As of 2025 Q4 — sorted by position size